================================================================================
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT: APRIL 24, 2007
(Date of earliest event reported)
LECTEC CORPORATION
(Exact name of registrant as specified in its charter)
Commission File Number: 0-16159
-------------------------------------
MINNESOTA 41-1301878
(State or other jurisdiction of incorporation) (IRS Employer Identification No.)
5610 LINCOLN DRIVE, EDINA, MINNESOTA 55436
(Address of principal executive offices, including zip code)
(952) 933-2291
(Registrant's telephone number, including area code)
NOT APPLICABLE
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
================================================================================
ITEM 8.01 OTHER EVENTS.
LecTec announced today that the United States Patent & Trademark Office (USPTO)
has completed a re-examination of LecTec's U.S. Patent No. 5,536,263 and has
issued a re-examination certificate for the patent. The '263 patent is entitled
"Non-Occlusive Adhesive Patch for Applying Medication to the Skin" and covers
the design for adhesive patches which contain a reservoir of medication to be
delivered into the body by absorption through the skin. Patches produced under
the '263 patent have been used for a number of applications including, among
others, the localized treatment of pain and the delivery by infusion of certain
medications for systemic conditions. The re-examination, which was commenced at
the request of LecTec in December 2000 in Application No. 90/005,877, concluded
with the issuance of the re-examination certificate on April 24, 2007.
Additional information concerning the re-issued patent can be obtained on the
USPTO website at www.uspto.gov.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
LECTEC CORPORATION
By: /s/ Judd A. Berlin
-----------------------------------
Judd A. Berlin
Chief Executive Officer and Chief
Financial Officer
Date: May 7, 2007
3